ORPHA:424080
Undifferentiated carcinoma with osteoclast-like giant cells of pancreas
Also known as: OGCT of pancreas · Osteoclastic giant cell tumor of pancreas · Pancreatic osteoclastic giant cell tumor · Pancreatic undifferentiated carcinoma with osteoclast-like giant cells · Undifferentiated carcinoma of pancreas with osteoclast-like giant cells
Publications
56
44.7th percentile
Trials
0
Interventional, condition-specific
Researchers
363
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare type of pancreatic ductal adenocarcinoma characterized by composition of non-neoplastic osteoclast-like multinucleated giant cells, a mononuclear histiocytic component, and the neoplastic cells, which vary from spindle-shaped to epithelioid and can be very large and pleomorphic. Clinical features of pancreatic ductal adenocarcinoma include abdominal pain, nausea, weight loss, jaundice, and new-onset diabetes.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0006479
- UMLS:C2007059
- NCIT:C5723
Additional Mondo synonyms (10)
osteoclast-like giant cell neoplasm of pancreas · osteoclast-like giant cell neoplasm of the pancreas · osteoclastic giant cell tumor of pancreas · osteoclastic giant cell tumour of pancreas · pancreatic osteoclast-like giant cell carcinoma · pancreatic osteoclastic giant cell tumor · pancreatic osteoclastic giant cell tumour · pancreatic undifferentiated carcinoma with osteoclast-like giant cells · undifferentiated carcinoma of pancreas with osteoclast-like giant cells · undifferentiated pancreatic carcinoma with osteoclast-like giant cells
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
56 matched papers (39 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 53 for broader category undifferentiated carcinoma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-27
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
56
56 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
56 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
39 in the last 10 years · high confidence · 44.7th percentile (publications denominator)
Phrase hits: 56 · MeSH hits: 0
Who's working on it?
363
Distinct author names in 56 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Wang X3 papers · 2025
Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. wxy@shsmu.edu.cn.
Papers in Europe PMC - 02Zhang S3 papers · 2022
Liver Research Center, Rhode Island Hospital, Warren Alpert Medical School, Brown University, 55 Claverick Street, 4th Fl., Providence, RI, 02903, USA.
Papers in Europe PMC - 03Capelli P2 papers · 2018
Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Papers in Europe PMC - 04Chen J2 papers · 2022
Department of Radiology, Sir Run Run Shaw hospital, Zhejiang University School of Medicine, Hangzhou City 310016, Zhejiang Province, China.
Papers in Europe PMC - 05Chianchiano P2 papers · 2018
Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Papers in Europe PMC - 06Jin Y2 papers · 2024
Department of Medical Imaging, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Papers in Europe PMC - 07Kong R2 papers · 2019
Department of Pancreatic and Biliary Surgery; Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, 150081, Heilongjiang Province, People's Republic of China.
Papers in Europe PMC - 08Li M2 papers · 2022
Immunobiology & Transplant Science Center, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Papers in Europe PMC - 09Luchini C2 papers · 2018
Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
Papers in Europe PMC - 10Mafficini A2 papers · 2018
ARC-Net Research Center, University of Verona, Verona, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 53 trials are registered for undifferentiated carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 9 September 2026 · last trial check 9 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
53 interventional trials matched undifferentiated carcinoma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: undifferentiated carcinoma
53
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05256225·RECRUITING·Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Conditions: Endometrial Carcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Dedifferentiated Carcinoma · Endometrial Endometrioid Adenocarcinoma·Matched via name phrase
- NCT06940180·RECRUITING·Toripalimab With Chemotherapy for Sinus Cancer
Conditions: Sinonasal Cancer · Paranasal Sinus Neoplasms · Squamous Cell Carcinoma · Sinonasal Undifferentiated Carcinoma·Matched via name phrase
- NCT06814496·RECRUITING·Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Conditions: Melanoma · Medullary Thyroid Cancer · Sinonasal Undifferentiated Carcinoma · Esthesioneuroblastoma·Matched via name phrase
- NCT05925491·RECRUITING·Pembrolizumab in Locally Advanced Sinonasal Carcinoma
Conditions: Sinonasal Undifferentiated Carcinoma·Matched via name phrase
- NCT06176989·RECRUITING·Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
Conditions: Metastatic Chondrosarcoma · Locally Advanced Chondrosarcoma · Metastatic Sinonasal Adenocarcinoma · Locally Advanced Sinonasal Adenocarcinoma·Matched via name phrase
- NCT05112601·RECRUITING·Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Conditions: Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Dedifferentiated Carcinoma · Endometrial Endometrioid Adenocarcinoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-27
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Undifferentiated carcinoma with osteoclast-like giant cells of pancreas — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Undifferentiated carcinoma with osteoclast-like giant cells of pancreas" OR "OGCT of pancreas" OR "Osteoclastic giant cell tumor of pancreas" OR "Pancreatic osteoclastic giant cell tumor" OR "Pancreatic undifferentiated carcinoma with osteoclast-like giant cells" OR "Undifferentiated carcinoma of pancreas with osteoclast-like giant cells" OR "osteoclast-like giant cell neoplasm of pancreas" OR "osteoclast-like giant cell neoplasm of the pancreas" OR "osteoclastic giant cell tumour of pancreas" OR "pancreatic osteoclast-like giant cell carcinoma" OR "pancreatic osteoclastic giant cell tumour" OR "undifferentiated pancreatic carcinoma with osteoclast-like giant cells"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Undifferentiated carcinoma with osteoclast-like giant cells of pancreas" OR "Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas" OR "OGCT of pancreas" OR "OGCT of the pancreas" OR "Osteoclastic giant cell tumor of pancreas" OR "Osteoclastic giant cell tumor of the pancreas" OR "Pancreatic osteoclastic giant cell tumor" OR "Pancreatic undifferentiated carcinoma with osteoclast-like giant cells" OR "Undifferentiated carcinoma of pancreas with osteoclast-like giant cells" OR "Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells" OR "osteoclast-like giant cell neoplasm of pancreas" OR "osteoclast-like giant cell neoplasm of the pancreas" OR "osteoclastic giant cell tumour of pancreas" OR "osteoclastic giant cell tumour of the pancreas" OR "pancreatic osteoclast-like giant cell carcinoma" OR "pancreatic osteoclastic giant cell tumour" OR "undifferentiated pancreatic carcinoma with osteoclast-like giant cells"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"undifferentiated carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T01:33:41.641Z